Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04827745
Title Blinatumomab for Treatment of R/R or MRD-positive CD19-Positive MPAL
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Maryland, Baltimore
Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.